(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 November 2025 (27.11.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/240992 A1

(51) International Patent Classification:
C07K 14/00 (2006.01) *C07K 19/00* (2006.01)
A61K 47/64 (2017.01) *C12N 15/113* (2010.01)
A61P 27/02 (2006.01) *C12N 15/87* (2006.01)

(21) International Application Number:
PCT/AU2025/050177

(22) International Filing Date:
28 February 2025 (28.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2024901550 24 May 2024 (24.05.2024) AU

(71) Applicant: **PYC THERAPEUTICS LIMITED** [AU/AU]; Harry Perkins Institute, 6 Verdun St, Nedlands, Western Australia 6009 (AU).

(72) Inventors: **MARTIN, Adam**; c/o PYC Therapeutics Limited, Harry Perkins Institute, 6 Verdun St, Nedlands, Western Australia 6009 (AU). **GRAINOK, Janya**; c/o PYC Therapeutics Limited, Harry Perkins Institute, 6 Verdun St, Nedlands, Western Australia 6009 (AU). **UTAMA, Sasiwimon**; c/o PYC Therapeutics Limited, Harry Perkins Institute, 6 Verdun St, Nedlands, Western Australia 6009 (AU).

(74) Agent: **FB RICE PTY LTD**; Level 33, 477 Collins St, Melbourne, Victoria 3000 (AU).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: AGENTS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH OPTIC ATROPHY 1

(57) Abstract: The present disclosure generally relates to a cell-penetrating peptide (CPP) comprising a sequence set forth in SEQ ID NO: 2504 and conjugates thereof. The present invention also relates to antisense oligonucleotides that modulates mRNA productive transcript, stability and/or translation of *OPA1* gene transcript or part thereof linked to a cell-penetrating peptide (CPP) comprising a sequence set forth in SEQ ID NO: 2504.

WO 2025/240992 A1